{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:12:02Z","timestamp":1794352322727,"version":"4.9.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The PhD studies Grant from Vilnius University","id":[{"id":"https:\/\/ror.org\/03nadee84","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The Research Council of Lithuania and Vilnius Gediminas Technical University","id":[{"id":"https:\/\/ror.org\/02x3e4q36","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triple negative breast cancer (TNBC) is an aggressive malignancy distinguished by resistance to standard breast cancer therapies. The absence of reliable prognostic tools hinders the ability to predict therapeutic response, resulting in some patients receiving treatment that is ineffective yet physically exhausting. miRNAs are small non-coding RNA molecules that regulate gene expression, and their dysregulated profiles in liquid biopsies hold immense potential as minimally invasive biomarkers for monitoring treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this study, we seek to identify miRNAs that may serve as predictive biomarkers for therapeutic responses in patients diagnosed with triple-negative breast cancer. To achieve this, an in silico analysis of the Cancer Genome Atlas (TCGA) dataset is conducted to narrow the list of candidate miRNAs. miRNAs with potential involvement in TNBC were selected for clinical validation in whole-blood samples of TNBC patients before and after therapy. The RT-qPCR-based expression analysis revealed significant predictive potential of\n                      <jats:italic>miR-340-5p<\/jats:italic>\n                      ,\n                      <jats:italic>miR-1307-3p<\/jats:italic>\n                      ,\n                      <jats:italic>miR-185-5p<\/jats:italic>\n                      , and\n                      <jats:italic>miR-30a-3p<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study identified that dysregulated miRNA signatures can serve as independent indicators for therapeutic monitoring. Notably, the combined multi-miRNA expression panel offers a robust, superior predictive value for stratifying treatment response and tracking disease progression in TNBC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41065-026-00712-8","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:45:03Z","timestamp":1783518303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Whole blood miRNA expression signatures as predictors of neoadjuvant chemotherapy response in triple-negative breast cancer"],"prefix":"10.1186","volume":"163","author":[{"given":"Monika","family":"Drobniene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domas","family":"Stitilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linas","family":"Kunigenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egle","family":"Strainiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonata","family":"Jarmalaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kestutis","family":"Suziedelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"712_CR1","unstructured":"Triple-negative. Breast Cancer | Details, Diagnosis, and Signs. Available: https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/about\/types-of-breast-cancer\/triple-negative.html Accessed: 3 Nov 2025."},{"key":"712_CR2","doi-asserted-by":"publisher","unstructured":"Gou Y et al. Dec., Integrated Pan-Cancer Profiling and Breast Cancer Validation Identify BEND3 as a Potential Prognostic and Immune Biomarker, Breast Cancer (Dove Med Press). 2025;17:1439\u20131461. https:\/\/doi.org\/10.2147\/BCTT.S553681.","DOI":"10.2147\/BCTT.S553681"},{"key":"712_CR3","doi-asserted-by":"publisher","unstructured":"Dent R et al. Aug., Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence, Clin Cancer Res. 2007;13(15):4429\u20134434. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045.","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"key":"712_CR4","doi-asserted-by":"publisher","unstructured":"Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor, Gynecol Oncol. 2010;119(3)586\u2013593. https:\/\/doi.org\/10.1016\/j.ygyno.2010.07.021.","DOI":"10.1016\/j.ygyno.2010.07.021"},{"key":"712_CR5","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz JP, P\u00e9rez-Moreno P, P\u00e9rez Y, Calaf GM. The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application. Diagnostics (Basel). 2023;13(19):3072. https:\/\/doi.org\/10.3390\/diagnostics13193072.","DOI":"10.3390\/diagnostics13193072"},{"key":"712_CR6","doi-asserted-by":"publisher","unstructured":"Anaparti V, Smolik I, Meng X, Spicer V, Mookherjee N, El-Gabalawy H. Whole blood microRNA expression pattern differentiates patients with rheumatoid arthritis, their seropositive first-degree relatives, and healthy unrelated control subjects, Arthritis Res Ther. 2017;19(1)249. https:\/\/doi.org\/10.1186\/s13075-017-1459-x.","DOI":"10.1186\/s13075-017-1459-x"},{"issue":"7","key":"712_CR7","doi-asserted-by":"publisher","first-page":"e41561","DOI":"10.1371\/journal.pone.0041561","volume":"7","author":"K Wang","year":"2012","unstructured":"Wang K, Yuan Y, Cho J-H, McClarty S, Baxter D, Galas DJ. Comparing the MicroRNA spectrum between serum and plasma. PLoS ONE. 2012;7(7):e41561. https:\/\/doi.org\/10.1371\/journal.pone.0041561.","journal-title":"PLoS ONE"},{"key":"712_CR8","doi-asserted-by":"publisher","unstructured":"H\u00f8gdall D, et al. Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer. J Hepatol. 2022;77(4):1047\u201358. https:\/\/doi.org\/10.1016\/j.jhep.2022.05.036.","DOI":"10.1016\/j.jhep.2022.05.036"},{"key":"712_CR9","doi-asserted-by":"publisher","unstructured":"Ding L, et al. MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance, and Applications in Human Triple-Negative Breast Cancer. Cells. 2019;8(12):1492. https:\/\/doi.org\/10.3390\/cells8121492.","DOI":"10.3390\/cells8121492"},{"key":"712_CR10","doi-asserted-by":"publisher","unstructured":"Yan L-J, Lau ATY, Xu Y-M. The regulation of microRNAs on chemoresistance in triple-negative breast cancer: a recent update, Epigenomics. 2024;16(8):571\u2013587. https:\/\/doi.org\/10.2217\/epi-2023-0430.","DOI":"10.2217\/epi-2023-0430"},{"key":"712_CR11","doi-asserted-by":"publisher","unstructured":"Comprehensive molecular portraits of human breast tumours,. Nature. 2012;490(7418). https:\/\/doi.org\/10.1038\/nature11412.","DOI":"10.1038\/nature11412"},{"key":"712_CR12","doi-asserted-by":"publisher","unstructured":"de Bruijn I, et al. Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023;83(23):3861\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0816.","DOI":"10.1158\/0008-5472.CAN-23-0816"},{"key":"712_CR13","doi-asserted-by":"publisher","unstructured":"Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095.","DOI":"10.1158\/2159-8290.CD-12-0095"},{"key":"712_CR14","doi-asserted-by":"publisher","unstructured":"Gao J et al. Apr., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal. 2013;6(269)1. https:\/\/doi.org\/10.1126\/scisignal.2004088.","DOI":"10.1126\/scisignal.2004088"},{"key":"712_CR15","doi-asserted-by":"publisher","unstructured":"Elizarraras JM, Liao Y, Shi Z, Zhu Q, Pico AR, Zhang B. WebGestalt 2024: faster gene set analysis and new support for metabolomics and multi-omics. Nucleic Acids Res. 2024;52(no. W1):W415\u201321. https:\/\/doi.org\/10.1093\/nar\/gkae456.","DOI":"10.1093\/nar\/gkae456"},{"key":"712_CR16","doi-asserted-by":"publisher","unstructured":"Karagkouni D, et al. DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA\u2013gene interactions. Nucleic Acids Res. 2018;46(no. D1):D239\u201345. https:\/\/doi.org\/10.1093\/nar\/gkx1141.","DOI":"10.1093\/nar\/gkx1141"},{"key":"712_CR17","doi-asserted-by":"publisher","unstructured":"Anaya J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput Sci. 2016;2:e67. https:\/\/doi.org\/10.7717\/peerj-cs.67.","DOI":"10.7717\/peerj-cs.67"},{"key":"712_CR18","doi-asserted-by":"publisher","unstructured":"Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data, J Proteome Res. 2019;18(2)623\u2013632. https:\/\/doi.org\/10.1021\/acs.jproteome.8b00702.","DOI":"10.1021\/acs.jproteome.8b00702"},{"issue":"6","key":"712_CR19","doi-asserted-by":"publisher","first-page":"e0234191","DOI":"10.1371\/journal.pone.0234191","volume":"15","author":"A-S Hamy","year":"2020","unstructured":"Hamy A-S, et al. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy. PLoS ONE. 2020;15(6):e0234191. https:\/\/doi.org\/10.1371\/journal.pone.0234191.","journal-title":"PLoS ONE"},{"key":"712_CR20","doi-asserted-by":"publisher","unstructured":"Yau C, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(21)00589-1.","DOI":"10.1016\/S1470-2045(21)00589-1"},{"key":"712_CR21","doi-asserted-by":"publisher","unstructured":"Symmans WF et al. Oct., Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy, J Clin Oncol. 2007;25(28):4414\u20134422. https:\/\/doi.org\/10.1200\/JCO.2007.10.6823.","DOI":"10.1200\/JCO.2007.10.6823"},{"key":"712_CR22","doi-asserted-by":"publisher","unstructured":"Chen C, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):e179. https:\/\/doi.org\/10.1093\/nar\/gni178.","DOI":"10.1093\/nar\/gni178"},{"key":"712_CR23","doi-asserted-by":"publisher","unstructured":"Hirschberger S, et al. Identification of suitable controls for miRNA quantification in T-cells and whole blood cells in sepsis. Sci Rep. 2019;9(1):15735. https:\/\/doi.org\/10.1038\/s41598-019-51782-w.","DOI":"10.1038\/s41598-019-51782-w"},{"key":"712_CR24","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101\u20138. https:\/\/doi.org\/10.1038\/nprot.2008.73.","journal-title":"Nat Protoc"},{"key":"712_CR25","doi-asserted-by":"publisher","unstructured":"Zhang S et al. May., Layered Double Hydroxide-Loaded miR-30a for the Treatment of Breast Cancer In Vitro and In Vivo, ACS Omega. 2023;8(21):18435\u201318448. https:\/\/doi.org\/10.1021\/acsomega.2c07866.","DOI":"10.1021\/acsomega.2c07866"},{"key":"712_CR26","doi-asserted-by":"publisher","unstructured":"Koustas E, et al. The Emerging Role of MicroRNAs and Autophagy Mechanism in Pancreatic Cancer Progression: Future Therapeutic Approaches. Genes. Oct. 2022;13(10):1868. https:\/\/doi.org\/10.3390\/genes13101868.","DOI":"10.3390\/genes13101868"},{"key":"712_CR27","doi-asserted-by":"publisher","unstructured":"Wu X, Kong C, Wu Y. Long intergenic non-protein coding RNA 1094 (LINC01094) promotes the progression of breast cancer (BC) by regulating the microRNA-340-5p (miR-340-5p)\/E2F transcription factor 3 (E2F3) axis, Bioengineered2021;12(1)9046\u20139057. https:\/\/doi.org\/10.1080\/21655979.2021.1993715.","DOI":"10.1080\/21655979.2021.1993715"},{"key":"712_CR28","doi-asserted-by":"publisher","unstructured":"Poggio F et al. Jul., Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis, Annals of Oncology. 2018;29(7)1497\u20131508. https:\/\/doi.org\/10.1093\/annonc\/mdy127.","DOI":"10.1093\/annonc\/mdy127"},{"key":"712_CR29","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1111\/1759-7714.15460","volume":"15","author":"JR Estupi\u00f1an-Jim\u00e9nez","year":"2024","unstructured":"Estupi\u00f1an-Jim\u00e9nez JR, et al. MicroRNA-1307-3p contributes to breast cancer progression through PRM2. Thorac Cancer. 2024;15:2298\u2013308. https:\/\/doi.org\/10.1111\/1759-7714.15460.","journal-title":"Thorac Cancer"},{"key":"712_CR30","doi-asserted-by":"publisher","unstructured":"Han S et al. Jan., miR-1307-3p Stimulates Breast Cancer Development and Progression by Targeting SMYD4, J Cancer. 2019;10(2)441\u2013448. https:\/\/doi.org\/10.7150\/jca.30041.","DOI":"10.7150\/jca.30041"},{"key":"712_CR31","doi-asserted-by":"publisher","unstructured":"Yin C, et al. miR-185-5p inhibits F-actin polymerization and reverses epithelial mesenchymal transition of human breast cancer cells by modulating RAGE. Mol Med Rep. 2018;18(3):2621\u201330. https:\/\/doi.org\/10.3892\/mmr.2018.9294.","DOI":"10.3892\/mmr.2018.9294"},{"key":"712_CR32","doi-asserted-by":"publisher","unstructured":"Shi R, Wu P, Liu M, Chen B, Cong L. Knockdown of lncRNA PCAT6 Enhances Radiosensitivity in Triple-Negative Breast Cancer Cells by Regulating miR-185-5p\/TPD52 Axis, OncoTargets and Therapy. 2020;13:3025\u20133037. https:\/\/doi.org\/10.2147\/OTT.S237559.","DOI":"10.2147\/OTT.S237559"},{"key":"712_CR33","doi-asserted-by":"publisher","unstructured":"De\u011ferli E, Torun V, Cansaran-Duman D. miR-185-5p response to usnic acid suppresses proliferation and regulating apoptosis in breast cancer cell by targeting Bcl2. Biol Res. 2020;53(1):19. https:\/\/doi.org\/10.1186\/s40659-020-00285-4.","DOI":"10.1186\/s40659-020-00285-4"},{"key":"712_CR34","doi-asserted-by":"publisher","unstructured":"De Luca G, et al. Fibroblasts activated by miRs-185-5p, miR-652-5p, and miR-1246 shape the tumor microenvironment in triple-negative breast cancer via PATZ1 downregulation. Cell Mol Life Sci. 2025;82(1):287. https:\/\/doi.org\/10.1007\/s00018-025-05781-y.","DOI":"10.1007\/s00018-025-05781-y"},{"key":"712_CR35","doi-asserted-by":"publisher","unstructured":"di Gennaro A, et al. A p53\/miR-30a\/ZEB2 axis controls triple negative breast cancer aggressiveness. Cell Death Differ. 2018;25(12):2165\u201380. https:\/\/doi.org\/10.1038\/s41418-018-0103-x.","DOI":"10.1038\/s41418-018-0103-x"},{"key":"712_CR36","doi-asserted-by":"publisher","unstructured":"Mitsueda R et al. Dec., Identification of Tumor-Suppressive miR-30a-3p Controlled Genes: ANLN as a Therapeutic Target in Breast Cancer, Non-Coding RNA2024;10(6):60. https:\/\/doi.org\/10.3390\/ncrna10060060.","DOI":"10.3390\/ncrna10060060"},{"key":"712_CR37","doi-asserted-by":"publisher","unstructured":"Adam-Artigues A, et al. Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer. ESMO Open. 2021;6(1):100039. https:\/\/doi.org\/10.1016\/j.esmoop.2020.100039.","DOI":"10.1016\/j.esmoop.2020.100039"},{"key":"712_CR38","doi-asserted-by":"publisher","unstructured":"Li D, Zhong J, Zhang G, Lin L, Liu Z. Oncogenic Role and Prognostic Value of MicroRNA-937-3p in Patients with Breast Cancer, OncoTargets and Therapy. 2019;12:11045\u201311056. https:\/\/doi.org\/10.2147\/OTT.S229510.","DOI":"10.2147\/OTT.S229510"},{"key":"712_CR39","doi-asserted-by":"publisher","unstructured":"Shi S, et al. LGR5 acts as a target of miR-340-5p in the suppression of cell progression and drug resistance in breast cancer via Wnt\/\u03b2-catenin pathway. Gene. 2019;683:47\u201353. https:\/\/doi.org\/10.1016\/j.gene.2018.10.014.","DOI":"10.1016\/j.gene.2018.10.014"},{"issue":"3","key":"712_CR40","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/cas.12880","volume":"107","author":"A Shimomura","year":"2016","unstructured":"Shimomura A, et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci. 2016;107(3):326\u201334. https:\/\/doi.org\/10.1111\/cas.12880.","journal-title":"Cancer Sci"},{"key":"712_CR41","doi-asserted-by":"publisher","unstructured":"Hu Z et al. Nov., Identification and validation of screening models for breast cancer with 3 serum miRNAs in an 11,349 samples mixed cohort, Breast Cancer. 2024;31(6)1046\u20131058. https:\/\/doi.org\/10.1007\/s12282-024-01619-w.","DOI":"10.1007\/s12282-024-01619-w"},{"key":"712_CR42","doi-asserted-by":"publisher","unstructured":"Schrauder MG, et al. Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection. PLoS ONE. 2012;7(1):e29770. https:\/\/doi.org\/10.1371\/journal.pone.0029770.","DOI":"10.1371\/journal.pone.0029770"},{"key":"712_CR43","doi-asserted-by":"publisher","unstructured":"Kleivi Sahlberg K, et al. A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients. Clin Cancer Res. 2015;21(5):1207\u201314. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2011.","DOI":"10.1158\/1078-0432.CCR-14-2011"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-026-00712-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00712-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00712-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:05:54Z","timestamp":1790906754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41065-026-00712-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["712"],"URL":"https:\/\/doi.org\/10.1186\/s41065-026-00712-8","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We confirm that the study complies with the Declaration of Helsinki and is approved by the Vilnius Regional Bioethics Committee (No. 2019\/2-1084-589). All patients have signed informed consents. We confirm that all methods were performed in accordance with the relevant guidelines and regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"102"}}